NASDAQ : KURA
Kura Oncology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.26 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 912.74M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 912.74M |
| Enterprise Value | 418.17M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 88.96M |
| Shares Outstanding | 88.96M |
| Shares Change (YoY) | +1.16% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 1.59% |
| Owned by Institutions (%) | 77.55% |
| Float | 70.53M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.82 |
| Forward PS | 6.21 |
| PB Ratio | 18.84 |
| P/TBV Ratio | 18.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.73 |
| Quick Ratio | 4.50 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -224.01 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -167.71% |
| Return on Assets (ROA) | -31.30% |
| Return on Invested Capital (ROIC) | -99.94% |
| Return on Capital Employed (ROCE) | -67.74% |
| Weighted Average Cost of Capital (WACC) | 6.77% |
| Revenue Per Employee | $297,019 |
| Profits Per Employee | -$1.14M |
| Employee Count | 260 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 84,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.47 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 11.15 |
| 200-Day Moving Average | 9.81 |
| Relative Strength Index (RSI) | 49.03 |
| Average Volume (20 Days) | 1,611,401 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 14.32M |
| Short Previous Month | 14.42M |
| Short % of Shares Out | 16.10% |
| Short % of Float | 20.30% |
| Short Ratio (days to cover) | 7.97 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 77.23M |
| Gross Profit | -182.81M |
| Operating Income | -318.09M |
| Pretax Income | -296.69M |
| Net Income | -296.78M |
| EBITDA | -316.80M |
| EBIT | -318.09M |
| Loss Per Share | -$3.36 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 519.03M |
| Total Debt | 24.46M |
| Net Cash | 494.57M |
| Net Cash Per Share | $5.56 |
| Equity (Book Value) | 48.43M |
| Book Value Per Share | 0.54 |
| Working Capital | 441.25M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -111.76M |
| Capital Expenditures | -5.67M |
| Depreciation & Amortization | 1.29M |
| Net Borrowing | n/a |
| Free Cash Flow | -117.43M |
| FCF Per Share | -$1.32 |
Margins
| Measure | Value |
|---|
| Gross Margin | -236.72% |
| Operating Margin | -411.90% |
| Pretax Margin | -384.19% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.16% |
| Shareholder Yield | -1.16% |
| Earnings Yield | -32.76% |
| FCF Yield | -12.87% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $31.85 |
| Price Target Difference | 210.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 61.91% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.02 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |